Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 52

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 8
Chunk 52
---
 cataracts, corneal, vitreous and retinal eye conditions, which includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery.The Company’s Chief Operating Decision Maker uses segment profit to assess operating performance and make resource allocation decisions for each of its segments. Segment profit is based on operating (loss) income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of Bausch + Lomb’s businesses and incurs certain expenses, gains and losses related to the overall management of Bausch + Lomb, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.Segment Revenues and Profit

28

Segment revenues and profits for the three and six months ended June 30, 2025 and 2024 were as follows:Vision CarePharmaceuticalsSurgicalTotalThree Months Ended June 30,(in millions)20252024202520242025202420252024RevenuesProduct Sales$751 $695 $307 $310 $214 $208 $1,272 $1,213 Other Revenues2 2 2 — 2 1 6 3 753 697 309 310 216 209 1,278 1,216 ExpensesCost of goods sold (excluding amortization and impairments of intangible assets)290 258 104 96 129 128 Cost of other revenues— — 2 1 — — Selling, general and administrative243 236 154 126 73 67 Research and development11 11 12 9 12 10 Segment Profit$209 $192 $37 $78 $2 $4 248 274 Corporate(170)(160)Amortization of intangible assets(67)(74)Other expense, net(22)(14)Operating (loss) income(11)26